Delivery Order SPE2DB20D3103-SPE2DB25FP7U6
Award Date 8/7/25
Potential Completion Date 8/8/25
Potential Value $15K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The U.S. Defense Logistics Agency Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $11,951.84 for RUXIENCE 500 mg/50 ml vials on August 19, 2025, with completion scheduled for August 20, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. RUXIENCE is a biosimilar to rituximab used in the treatment of various cancers...
- The Defense Logistics Agency awarded a delivery order valued at $13,014.23 to AmerisourceBergen Drug Corp for Ruxience 500 mg/50 mL vials on May 12, 2025, with a completion date of May 13, 2025. This firm fixed-price delivery order, issued without a set-aside designation, will be performed at the contractor's location in Conshohocken, Pennsylvania. Ruxience is a biosimilar medication used in oncology and immunology treatments, reflecting the agency's ongoing need to supply critical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ruxience 500 mg/50 mL vials, valued at $13,824.28 under a firm fixed-price arrangement. This non-set-aside delivery order was awarded on July 8, 2025, with an ultimate completion date of July 9, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Ruxience is a biosimilar monoclonal antibody used in the treatment of various cancers and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Ruxience 500 mg/50 mL vials, a biosimilar medication used in cancer treatment. This firm fixed-price delivery order, valued at $7,421.74, represents a non-set-aside competitive award with an ultimate completion date of August 13, 2025. The pharmaceutical products will be supplied to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a $6,413.75 firm fixed price delivery order to Amerisourcebergen Drug Corp for Ruxience 500 MG/50 ML vials. As the prime contractor, Amerisourcebergen Drug Corp will deliver 50 ML vials of the biosimilar drug Ruxience to its Conshohocken, Pennsylvania location by August 10, 2023 to support the Defense Logistics Agency's medical supply needs. The delivery order was issued under an existing Amerisourcebergen Corporation indefinite-delivery/indefinite-quantity...
- The Defense Logistics Agency awarded a $39,673.94 delivery order to AmerisourceBergen Drug Corp for the supply of Ruxience 500 mg/50 ml vials on August 29, 2025, with an ultimate completion date of September 2, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The place of performance is located in...
- This delivery order awards AmerisourceBergen Drug Corp a firm fixed-price contract valued at $1,467.66 for the supply of Ruxience 500 mg/50 ml vials. The contract was awarded competitively without a set-aside designation on April 28, 2025, with an ultimate completion date of April 29, 2025. The Defense Logistics Agency (DLA), through its federal medical procurement operations, is funding this award. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania,...
- AmerisourceBergen Drug Corp received a $21,846.24 firm fixed-price delivery order from the Defense Logistics Agency (DLA) for 500 mg/50 mL vials of Ruxience, a biosimilar medication, with an ultimate completion date of September 11, 2025. This non-set-aside award was competitively issued and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with...
- This is a $3,404.70 firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Ruxience 500 mg/50 ml vials. The order is not set aside and has an ultimate completion date of August 28, 2024. AmerisourceBergen holds several indefinite delivery contracts (IDCs) with federal agencies, including a $999,999,999 IDC with DLA Troop Support Medical for delivering a wide range of medical commodities...
- This is a delivery order federal contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,484.87, is for the provision of 500 mg/50 ml vials of the pharmaceutical product Ruxience. This order is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The...